Literature DB >> 25676419

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells.

L Lu1, V A Saunders2, T M Leclercq1, T P Hughes3, D L White4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25676419     DOI： 10.1038/leu.2015.35

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

Authors:  Deborah L White; Jerald Radich; Simona Soverini; Verity A Saunders; Amity K Frede; Phuong Dang; Daniela Cilloni; Peter Lin; Lidia Mongay; Richard Woodman; Paul Manley; Cassandra Slader; Dong Wook Kim; Fabrizio Pane; Giovanni Martinelli; Giuseppe Saglio; Timothy P Hughes
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

3.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Authors:  Herman Burger; Hans van Tol; Mariël Brok; Erik A C Wiemer; Ernst A de Bruijn; Gunther Guetens; Gert de Boeck; Alex Sparreboom; Jaap Verweij; Kees Nooter
Journal:  Cancer Biol Ther       Date:  2005-07-09       Impact factor: 4.742

4.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.

Authors:  C Pauli-Magnus; S Rekersbrink; U Klotz; M F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-12       Impact factor: 3.000

5.  Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

Authors:  Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Amity Venables; Stephanie Zrim; Andrew Zannettino; Kevin Lynch; Paul W Manley; Timothy Hughes
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

6.  Active transport of imatinib into and out of cells: implications for drug resistance.

Authors:  Julia Thomas; Lihui Wang; Richard E Clark; Munir Pirmohamed
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

7.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

Authors:  Csilla Ozvegy-Laczka; Tamás Hegedus; György Várady; Olga Ujhelly; John D Schuetz; András Váradi; György Kéri; László Orfi; Katalin Német; Balázs Sarkadi
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

8.  Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Authors:  Devendra K Hiwase; Verity Saunders; Duncan Hewett; Amity Frede; Stephanie Zrim; Phuong Dang; Laura Eadie; L Bik To; Junia Melo; Sharad Kumar; Timothy P Hughes; Deborah L White
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

9.  Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Authors:  Carine Tang; Lisa Schafranek; Dale B Watkins; Wendy T Parker; Sarah Moore; Jodi A Prime; Deborah L White; Timothy P Hughes
Journal:  Leuk Lymphoma       Date:  2011-06-30

10.  Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.

Authors:  J Wang; T P Hughes; C H Kok; V A Saunders; A Frede; K Groot-Obbink; M Osborn; A A Somogyi; R J D'Andrea; D L White
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640
View more
  12 in total

Review 1.  Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.

Authors:  Marjan Yaghmaie; Cecilia Cs Yeung
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 2.  Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

Authors:  Veerandra Kumar; Priyanka Singh; Sonu Kumar Gupta; Villayat Ali; Malkhey Verma
Journal:  Mol Cell Biochem       Date:  2022-02-07       Impact factor: 3.396

Review 3.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

Review 4.  Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Daru       Date:  2020-01-03       Impact factor: 3.117

5.  Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Authors:  Jueqiong Wang; Liu Lu; Chung H Kok; Verity A Saunders; Jarrad M Goyne; Phuong Dang; Tamara M Leclercq; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

Review 6.  Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.

Authors:  Daphne Bertholee; Jan Gerard Maring; André B P van Kuilenburg
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 7.  Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.

Authors:  Raquel C Maia; Flavia C Vasconcelos; Paloma S Souza; Vivian M Rumjanek
Journal:  Molecules       Date:  2018-01-07       Impact factor: 4.411

8.  Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.

Authors:  W Qiang; O Antelope; M S Zabriskie; A D Pomicter; N A Vellore; P Szankasi; D Rea; J M Cayuela; T W Kelley; M W Deininger; T O'Hare
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

Review 9.  Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.

Authors:  Marialuisa Polillo; Sara Galimberti; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo
Journal:  Int J Mol Sci       Date:  2015-09-21       Impact factor: 5.923

10.  Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.

Authors:  H Jonathan G Lindström; Ran Friedman
Journal:  Sci Rep       Date:  2022-03-25       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.